中国结合医学杂志（英文版）Chinese Journal of Integrative Medicine

INTRODUCTION Lung cancer (LC) is one of the most prevalent malignancies with high mortality and poor prognosis(1). In 1990, LC represented 12.8% of the total new cancer cases and 17.8% of the total cancer deaths, while five-year survival was only 11%(1). Current management for LC includes surgery for localised tumours, and chemotherapy or radiotherapy for those at an advanced stage when tumours have spread to other organs(2). Patient resistance to these approaches, which is often based on concerns about adverse reactions, may reduce the acceptance of these therapies by LC patients(3,4).